Health-e News

Twice-yearly HIV prevention shot priced at $40 — what it means for South Africa

What’s new Why it matters The catch What they’re saying “This scenario of opaque pricing, restrictive licensing and inadequate global targets will leave far too many people at continued risk of preventable HIV infections,” says Antonio Flores, Senior HIV/TB Advisor at MSF’s Southern Africa Medical Unit. “South Africa cannot afford to repeat past mistakes- it must move quickly to secure lenacapavir for key populations and push for broader access across the region.” “Generic manufacture of lenacapavir is essential to ensure this breakthrough HIV prevention option is not limited to a privileged few,” says Professor Saiqa Mullick, Director of Implementation Science at Wits RHI, University of the Witwatersrand. “By driving prices down and securing sustainable supply, generics will make six-monthly PrEP a real choice for the millions of people in great need in low- and middle-income countries.”-Health-e News

This post Twice-yearly HIV prevention shot priced at $40 — what it means for South Africa first appeared on Health-e News and is written by Health-e News

Comment

Your email address will not be published. Required fields are marked *